We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here

News

Future treatment approaches in Mantle Cell Lymphoma

Tuesday, March 15, 2016

Peter Martin, M.D., associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, spoke to OncLive about future treatment approaches in the field of mantle cell lymphoma (MCL).

Over the next decade, the field will evolve significantly to include less aggressive treatment for younger patients, Martin predicts. While some patients are appropriately treated with aggressive therapy, others do not respond or are not required to receive such treatment. Clinical trials in development may help address this unmet need for younger patients, he adds.

Researchers are in the process of utilizing a new line of therapies, including Bruton’s tyrosine kinase inhibitors, PI3 kinase inhibitors, Bcl-2 inhibitors, immunomodulatory drugs, and immunotherapy agents. These therapies all have varying degrees of activity, Martin explains, adding that some of them may be even more responsive when given to patients in the frontline setting.